As a new-type foreign trade service provider driven by technological transformation and foreign trade services, HiSiaddi has established a "1+2+3+4=1" service system and can supply chondroitin sulfate sourced directly from multiple well-known original manufacturers.
Endowed with R&D capabilities, HiSiaddi has repeatedly conducted multi-round inspections of chondroitin sulfate brand enterprises through technological transformation cooperation with manufacturers, gaining objective and in-depth understanding of varying brand conditions. Accordingly, we frequently analyze different chondroitin sulfate manufacturers for clients to help them identify matching products. Below is a brand recommendation case.
Should you require comparative analysis of brands and models, please contact HiSiaddi customer service.
The cooperating entity is JOINTEC, a nutrition company headquartered in Munich, Germany. For over 30 years, it has specialized in high-end medical bone and joint dietary supplements and sports nutrition raw materials for professional sports leagues in Germany, a mid-to-high-end local brand whose products are sold in premium German organic pharmacy chains, physical therapy supply chains for Bundesliga clubs, and community rehabilitation medical institutions across Germany. All finished products comply with the European Pharmacopoeia (EP), United States Pharmacopeia (USP), German LFGB food access specifications, and TSE/BSE animal source safety control standards. The brand rejects low-cost feed-grade and bulk low-end food-grade raw materials, maintaining stable annual chondroitin sulfate procurement of 32 tons exclusively for proprietary formula high-end health products – distinct from low-price mass distribution buyers targeting budget supermarkets.
Previously, the client sourced pharmacopoeia-grade shark-derived chondroitin sulfate from Dutch pharmaceutical manufacturers year-round. Constrained by shrinking European raw material production capacity, cumulative 30% year-on-year raw material price hikes, and extended ocean delivery cycles of 115 days, the client launched a domestic Chinese raw material localization screening and procurement project in 2025. It independently contacted five leading domestic chondroitin sulfate manufacturers (Yantai Dongcheng, Zhejiang Hengjie, Shandong Jinyang, Sichuan Huigukang, Hebei Changshan Biochemical) at industry exhibitions for inquiries and sample requests, yet encountered obvious deadlock during product selection: sales staff from all five manufacturers focused solely on highlighting advantages of their own products and pushing flagship models. While compliant businesses avoided slandering competitors, they declined to objectively elaborate on strengths, weaknesses, and applicable scenarios of peer brands’ products. Lacking awareness of China’s raw material market brand, grade, and model systems, the client could not horizontally benchmark physical and chemical indicators, process routes, and compliance qualifications of each brand. Eight distinct sample models received triggered three production issues during client small-scale trials: insufficient tablet fluidity, unqualified softgel dissolution, and low-temperature precipitation of oral liquids, resulting in auxiliary material and sample losses exceeding EUR 56,000 and a 45-day delay to new product launch schedules. Trapped by asymmetric brand information and one-sided manufacturer product promotion, the client entrusted HiSiaddi as a neutral third party to systematically disassemble mainstream domestic leading brands and full-series model parameters, conduct horizontal comparative analysis of advantages and disadvantages, and screen compatible raw materials aligned with the client’s formulation requirements.
Mandatory product selection benchmarks specified by the client: Compatible for simultaneous production of softgels, sustained-release tablets, and oral liquids; bovine trachea-derived raw materials preferred; HPLC-determined content ≥95%, free protein ≤0.8%, molecular weight 19,000–22,000 Da, powder repose angle ≤32%; products must hold FDA DMF filings and EDQM-CEP European Pharmacopoeia certifications to meet German customs and local pharmaceutical administration entry verification standards.
The client contacted five first-tier domestic leading manufacturers, all equipped with complete GMP and ISO22000 qualifications, yet all adopted a sales model prioritizing in-house product promotion over objective competitor introductions – this constitutes the core driver of the client’s misaligned product selection.
1.
Yantai Dongcheng Pharmaceutical Sales representatives primarily promoted its EP98 pharmacopoeia-grade shark-derived chondroitin sulfate, emphasizing possession of EDQM CEP certificates, FDA DMF filings, and participation in European Pharmacopoeia monograph drafting, alongside industry-leading pharmaceutical-grade mass production capacity. When the client inquired about advantages of Hengjie and Jinyang products, responses were limited to “each enterprise adopts different processes, and our products better suit European pharmaceutical markets.” The manufacturer failed to disclose key parameters of competing raw materials (source, molecular weight, powder physical properties) and deliberately downplayed cost-effective bovine-derived product lines, misleading the client to prioritize high-priced shark-derived models with excessively large molecular weights incompatible with the client’s enteric softgel dissolution requirements.
2.
3.
Zhejiang Hengjie Biotechnology Two flagship models (self-developed Mini small-molecule series and ELASEM high-end food grade) were promoted, highlighting proprietary low-temperature enzymatic hydrolysis and membrane classification patent technologies with expertise in narrow molecular weight customization. When asked about characteristics of Dongcheng’s pharmacopoeia-grade and Jinyang’s high-purity food-grade products, staff only stated “product positioning differs” without objectively explaining Dongcheng’s advantages in injection auxiliary materials and Jinyang’s mass production stability. The promoted small-molecule model delivered only 93.5% content, failing to meet the client’s ≥95% minimum content threshold.
4.
5.
Shandong Jinyang Biotechnology The brand prioritized GY-95 high-purity bovine-derived general pharmacopoeia-grade products with prominent pricing advantages from large-scale mass production, emphasizing stable raw material traceability and minimal batch-to-batch variation for bulk goods. It avoided elaborating on Hengjie’s small-molecule modification strengths and Huigukang’s marine source cost-performance advantages, guiding clients exclusively to purchase its mass-produced generic products. Uneven particle size distribution of delivered samples triggered tablet stratification during production trials.
6.
7.
Sichuan Huigukang Biotechnology Operating full-grade multi-source (bovine/chicken/shark) products covering standard 90% food-grade to 98% pharmaceutical-grade specifications, the brand prioritized cost-effective 95% chicken-derived grades, highlighting raw material cost advantages without disclosing qualification barriers of Dongcheng and Hengjie in supporting high-end European formulations. Recommended chicken-derived raw materials contained excessive trace allergens, violating allergen control requirements for German medical food raw materials.
8.
9.
Hebei Changshan Biochemical Focused on pharmaceutical raw material injection-grade specifications, the brand promoted CS98 high-purity injection-grade chondroitin sulfate with internal control standards benchmarking Chinese pharmacopoeia, intentionally guiding clients to upgrade to ultra-high-purity pharmaceutical-grade models at quotations far exceeding the client’s budget without informing buyers that mid-to-high-end 95% dietary-grade products fully met the client’s formulation production requirements, inflating selection costs unnecessarily.
10.
No malicious competitor slander occurred among the five manufacturers, yet sales incentive constraints biased information output, leaving the client without neutral data support and resulting in eight incompatible sample batches selected solely based on unilateral manufacturer introductions, stalling product selection work.
HiSiaddi assembled a dedicated team of raw material technical specialists, foreign trade compliance specialists, and formulation application engineers. Adopting a neutral third-party perspective aligned with the German client’s three-dosage-form production parameters, the team collected Certificates of Analysis, qualification documents, process data, and end-user application cases for all five brands, conducting itemized disassembly and comparison across eight dimensions: raw material source, purity grade, molecular weight range, powder characteristics, international certifications, compatible dosage forms, price brackets, and strengths/weaknesses, objectively listing advantages and disadvantages of all full-series models for each brand:
Flagship models: ① EP98 shark-derived pharmacopoeia grade (98% content, for injections and high-end prescription drug excipients, complete EDQM and FDA filings, molecular weight 25,000–30,000 Da, premium pricing, compatible with injections and high-end prescription drugs; weakness: excessively large molecular weight leading to poor enteric softgel dissolution); ② USP95 bovine-derived dietary pharmacopoeia grade (95.2% content, extracted from bovine trachea, molecular weight 20,000 Da±1,000 Da, air flow classified powder with repose angle of 31°, complete European and American market access certifications; strength: indicators perfectly aligned with dietary supplements; weakness: high minimum mass production order quantity).
Brand summary: Possesses the most comprehensive pharmaceutical certifications with dominant advantages in high-end pharmaceutical lines. The USP95 bovine-derived model is optimized for dietary health products yet deliberately deprioritized in manufacturer sales outreach in favor of high-priced shark-derived models.
Flagship models: ① Mini-Pote small-molecule grade (93.5% content, narrow molecular weight range of 12,000–15,000 Da, low-temperature enzymatic hydrolysis modification optimized for high-absorption oral liquids; weakness: insufficient 95% content threshold, unstable tablet hardness post-compression); ② ELASEM-Bio USP95 standard grade (95.1% content, controllable molecular weight of 19,500 Da, optimized powder modification compatible with all three dosage forms; strength: flexible processes supporting fine-tuned indicators; weakness: slightly higher quotations for small-batch orders).
Brand summary: Industry leader in small-molecule modification with top-tier compatibility for oral liquids. The ELASEM-Bio universal mid-to-high-end model is an under-promoted flagship product, while manufacturers prioritize pushing their blockbuster small-molecule series.
Flagship models: ① GY-95 high-purity bovine-derived general grade (HPLC 95.0%±0.3%, fixed molecular weight of 21,000 Da, automated mass production with exceptional batch-to-batch stability, air flow classified powder with repose angle of 31.5°, NSF and ISO22000 certifications; weakness: no EDQM CEP certificates rendering it ineligible for German prescription drugs yet fully compliant for dietary supplements); ② GY-90 standard food grade (90% content, exclusively for low-budget supermarket health products).
Brand summary: Delivers leading cost-performance for bulk mass-produced dietary-grade raw materials fully compliant with European and American dietary supplement regulations; the sole limitation is absence of high-end European pharmaceutical raw material certifications.
Flagship models: ① HG95 chicken-derived food grade (95% content, low cost, extracted from chicken cartilage with elevated allergen levels, compatible with pet food and budget health products); ② HG96 shark-derived marine grade (96% content, marine raw materials at premium pricing for niche customized orders). Weaknesses: Incomplete bovine-derived product lines, incompatible with allergen control requirements for German medical food raw materials.
Flagship model: CS98 pharmaceutical injection grade (98.5% ultra-high purity exclusively for domestic injections, redundant indicators exceeding dietary-grade requirements with quotations 40% higher than dietary grades, surpassing the client’s budget). Weak supporting dietary-grade product lines render it unsuitable for the client’s health product formulation needs.
After completing five-brand data collation, HiSiaddi compiled measured sample data and European peer client application cases, eliminating four incompatible models: Huigukang chicken-derived grade, Changshan injection grade, Dongcheng shark-derived 98% grade, and Hengjie small-molecule 93.5% grade.
Drawing on horizontal benchmarking data and the client’s three-dosage-form formulation parameters, HiSiaddi selected two core mid-to-high-end brands (Dongcheng Pharmaceutical and Shandong Jinyang) and finalized three precisely compatible models for primary and backup supply, balancing product stability, compliance certifications, and procurement costs:
1. Model 1: USP95 bovine-derived pharmacopoeia grade (main bulk supply): HPLC content of 95.2%, molecular weight 20,000 Da±800 Da, free protein 0.65%, repose angle 31°, complete FDA DMF, EDQM, and LFGB certifications, perfectly compatible with tablet and softgel production, designated for the 24-ton primary annual order volume with full batches passing German customs and pharmaceutical administration sampling inspections.
2. Model 2: EL limited revised USP95 modified grade (small-batch oral liquid exclusive): Low-temperature water solubility modifications applied to baseline USP95 indicators to eliminate precipitation under weak acid refrigerated storage, exclusively supplied for the client’s high-end oral liquid product line with an 8-ton annual procurement volume produced via flexible pilot workshop scheduling at Dongcheng.
GY-95 national standard high-purity grade: 95.0% content, molecular weight 21,000 Da, powder physical indicators closely aligned with Dongcheng’s products, complete NSF, ISO22000, and TSE/BSE export documentation. Absence of European Pharmacopoeia CEP certificates disqualifies it for pharmaceutical use yet fully complies with dietary supplement regulations at quotations 18% lower than Dongcheng’s products, reserved as backup supplementary supply during peak production capacity shortages with allocated annual flexible procurement quotas.
HiSiaddi coordinated complimentary sample delivery of the three finalized models from both manufacturers, with the client conducting full-dosage-form pilot production at its German facility: Dongcheng’s standard USP95 main model eliminated tablet delamination and cracking, delivered 89.1% dissolution within 45 minutes for enteric softgels, and maintained clear oral liquid formulations without precipitation after 60 days of ambient and refrigerated storage. The revised oral liquid-exclusive grade further optimized low-temperature stability. All physical and chemical indicators of Jinyang’s GY-95 grade met standards, with the sole limitation of missing CEP pharmaceutical certifications restricting it to backup supply. All three products passed full-item testing at Germany’s AENOR third-party laboratory, prompting the client to issue a product selection confirmation letter.
Total annual procurement volume of 32 tons split into six monthly production batches: 24 tons of Dongcheng’s standard USP95 grade and 8 tons of oral liquid modified customized grade. Jinyang’s GY-95 grade remained reserved as backup inventory for supplementary procurement upon client peak production expansion. HiSiaddi oversaw pre-delivery SGS sampling testing, bilingual Chinese-English Certificates of Analysis, and full customs clearance compliance documentation for each batch, with goods shipped in batches from Qingdao Port to Hamburg Port without quality non-compliance incidents. The delayed new product line launched onto premium German pharmacy channels as scheduled.
Cost optimization: Comprehensive procurement costs decreased by 25.7% compared with raw materials previously imported from the Netherlands, and ocean delivery cycles shortened from 115 days to 38 days, drastically improving supply chain turnover efficiency.
1. JOINTEC Group of Germany fully terminated Dutch raw material imports, shifting 100% of its annual 32-ton raw material sourcing to domestic supply selected via HiSiaddi. A new customized demand for children’s medical food small-molecule chondroitin sulfate emerged the following year, leveraging product selection experience from this project to re-select Hengjie’s ELASEM-Bio model for an additional 11-ton annual procurement volume;
2. The client entrusted HiSiaddi to build a domestic raw material brand grading database, delegating all subsequent procurement of glucosamine, MSM, and other raw materials to HiSiaddi for neutral product selection to eliminate selection errors caused by one-sided manufacturer promotion;
3. Drawing on this multi-brand neutral product selection case, HiSiaddi sequentially secured raw material screening business from three peer mid-to-high-end nutrition brands in Austria and Switzerland.
Leading domestic chondroitin sulfate manufacturers feature comprehensive product matrices covering standard food-grade to high-end pharmaceutical pharmacopoeia-grade specifications, yet sales performance incentives drive them to prioritize flagship blockbuster products without objectively elaborating competing brands’ compatible strengths and weaknesses. Mid-to-high-end European health product enterprises rely on proprietary refined formulations with stringent raw material selection requirements for indicators, certifications, and dosage-form compatibility. Lacking awareness of China’s domestic brand landscape, independent manufacturer engagement traps buyers in information silos, risking selection of overpriced or indicator-mismatched products guided by manufacturer sales outreach. Breaking the traditional foreign trade model bound to single manufacturers and biased supplier advocacy, HiSiaddi horizontally disassembles strengths and weaknesses of multiple brands from a neutral third-party perspective, conducting precise raw material screening aligned with the client’s terminal formulation requirements. It helps mid-to-high-end European clients break through brand information barriers, cut procurement costs, and smoothly deliver domestic raw material substitution, while incentivizing domestic manufacturers to optimize full-product-line promotion frameworks and drive high-quality mid-to-high-end domestic raw materials to continuously penetrate premium European dietary supply chains – delivering long-term win-win outcomes for both supply and demand sides.
Should you require comparative analysis of brands and models, please contact HiSiaddi customer service.
1. ARTROCARE Group of Spain fully terminated procurement from European manufacturers, shifting 100% of its annual 36-ton raw material sourcing to HiSiaddi’s modified domestic supply. A new customized demand for small-molecule chondroitin sulfate for children’s medical food oral liquids emerged the following year, adding annual procurement volume of 12.5 tons;
2. Leveraging formulation adaptation technical insights accumulated from this rectification project, HiSiaddi assisted cooperating manufacturers in formalizing standardized processes for graded chondroitin sulfate compatible with multiple dosage forms, successfully developing two peer mid-to-high-end nutrition brand clients in Portugal and Italy;
3. The client entrusted HiSiaddi to establish pre-delivery raw material testing standards, requiring pre-production small-scale dosage-form trials for all raw material batches shipped in the future to eliminate hidden mass production technical risks at the source.
Domestic chondroitin sulfate manufacturers generally focus on raw material extraction and purification processes, adopting national and pharmacopoeia physical and chemical indicators as factory release acceptance standards, yet lack expertise in downstream formulation R&D and terminal mass production processes. They can only guarantee compliance of individual raw material indicators without predicting chain reactions triggered by raw material physical property fluctuations on tablets, softgels, and oral liquids. Proprietary formula-based finished products of mid-to-high-end European medical food enterprises feature deep binding between raw material physical properties and terminal formulations; minor fluctuations in raw material physical and chemical indicators may trigger full production line scrapping, trapping clients in a technical deadlock defined as “raw materials meet standard indicators yet finished mass production fails” when manufacturers are contacted independently. Breaking the traditional foreign trade model limited to raw material supply matching, HiSiaddi centers full-chain technical services to connect raw material production modification, downstream formulation optimization, and terminal process guidance across all technical links, disassembling failure root causes from a neutral perspective balancing supply and demand. It helps mid-to-high-end European clients resolve mass production technical failures, recover economic losses, and smoothly deliver domestic raw material substitution, while supporting domestic manufacturers to optimize product portfolios, escape homogenized low-price competition, and enter high-end European medical food raw material supply chains – achieving win-win outcomes for both supply and demand sides.
Should you require formulation optimization consulting services, please contact HiSiaddi customer service.
+86-13120989737 
info@hisiaddi.com 
English
